Introduction
The p53 tumour suppressor protein (for reviews see Gottlieb and Oren, 1996; Ko and Prives, 1996 ) is a potent transcription factor which is activated in response to a variety of cellular stresses including DNA damage, heat shock, hypoxia, cytokines, metabolic changes, viral infection and activated oncogenes, and is considered to be an integrator of these signals (Hall et al., 1996; Jacks and Weinberg, 1996) . Activation of p53 can lead to cell growth arrest at the G1 (Kastan et al., 1991 Kuerbitz et al., 1992) or G2 (Aloni et al., 1995; Cross et al., 1995; Paules et al., 1995) phases of the cell cycle, or the induction of apoptosis (Shaw et al., 1992; Yonish et al., 1991) and is thought to prevent the proliferation of genetically damaged cells (Lane, 1993) . Consequently, loss of p53 function, through mutation, which is a common occurrence in the development of tumours (Hollstein et al., 1991) , is a central event in the progression of the disease (Kinzler and Vogelstein, 1996) .
The activity of p53 is regulated at dierent levels and includes control by multi-site phosphorylation (reviewed by Meek, 1994) . Multi-site phosphorylation of the N-terminus of p53 is thought to provide a synergistic mechanism which can stimulate p53-dependent transactivation, growth arrest and suppression of cellular transformation (Fiscella et al., 1993; Lohrum and Scheidtmann, 1996; Mayr et al., 1995) . At least six sites within the N-terminal 83 amino acids of p53 are phosphorylated in vivo and several dierent protein kinases have been identi®ed which phosphorylate these sites in vitro, including DNA-activated protein kinase (DNA-PK) (Lees-Miller et al., 1990) , MAP kinase (Milne et al., 1994) and the u.v.-and stress-inducible kinase JNK1 (Milne et al., 1995) ; p53 can also be phosphorylated by high levels of casein kinase 1a (the major isoform of the casein kinase 1 (CK1) family ).
Five members of the CK1 family have now been cloned from mammalian cells (isoforms a, b, g, d , and e; (Fish et al., 1995; Graves et al., 1993; Rowles et al., 1991) ; reviewed by Christenson et al., 1996) . These show striking similarity within their kinase domains but can dier extensively in their C-terminal noncatalytic domains. The sites in p53 phosphorylated by CK1 (serines 4, 6 and 9 in mouse p53) and DNA-PK (serine 15) are the most highly phosphorylated sites in the protein (Meek, 1994) , and are turned over rapidly, consistent with an acute role in regulation (our unpublished data). Although CK1a can phosphorylate these N-terminal sites in vitro, it is not thought to phosphorylate p53 in vivo . Moreover, little is known about the signalling mechanism(s) which regulates the modi®cation of p53 at these sites, nor are the stimuli to which such a signalling pathway responds known. Our ®nding that p53 is preferentially phosphorylated by a CK1-like enzyme, which is separable from CK1a by anity chromatography, suggests that p53 is phosphorylated in the cell by a CK1 isoform or a highly related kinase . Moreover, the potential interaction of p53 with members of the CK1 family is of striking interest since CK1 family members play an integral role in resistance to radiation and DNA damage in yeasts and Drosophila (Dhillon and Hoekstra, 1994; Hoekstra et al., 1991) . Finally, our recent observation that p53 N-terminus-targeted protein kinase (p53NK) activity can be stimulated by anti-tumour drugs which elicit DNA damage (Knippschild et al, 1996) makes the identi®cation of this kinase(s) and characterisation of its interaction with p53 a major goal in understanding the mechanisms which activate and control p53 function.
In this paper we present evidence that p53 can be phosphorylated in vitro by the delta and epsilon isoforms of CK1 (CK1d and CK1e) respectively which are highly related to each other (Fish et al., 1995; Graves et al., 1993) and show that the identity of the cellular p53NK is entirely consistent with CK1d and CK1e. We also provide compelling evidence that p53 is phosphorylated in vivo by these kinases. Furthermore, we show that level of CK1d is in¯uenced by the presence of wild type p53, suggesting the possibility that the levels of p53 and CK1d may be interdependent.
Results

p53 is phosphorylated in vitro at N-terminal sites by the delta and epsilon isoforms of CK1
We have shown previously that serines 4, 6 and 9 of murine p53 are phosphorylated by a CK1-like enzyme(s) which we have termed p53-N-terminustargeted kinase (p53NK; Knippschild et al., 1996; . Analysis of partially puri®ed p53NK (see Materials and methods) using a`blotted protein kinase' assay with p53 as substrate (Ferrell and Martin, 1991) revealed a single species of kinase with a molecular weight of 49 000 (data not shown) consistent with the identity of the p53 kinase as either the delta (d) or epsilon (e) isoform of CK1, but not other CK1 isoforms which are considerably smaller (a, b and g; Christenson et al., 1996) . CK1d and CK1e show both striking sequence similarity (98% within the kinase domains (Fish et al., 1995; Graves et al., 1993; DeMaggio AJ, Christenson E and Hoekstra MF, submitted) and functional similarity (DeMaggio AJ, Christenson E and Hoekstra MF, submitted). To determine whether p53 was a substrate for either of these enzymes, the ability of recombinant CK1d or CK1e to phosphorylate a number of GST-p53 fusion proteins was measured. The data indicate that both FP267 (N-terminal 64 amino acids of murine p53) and casein were substrates for the recombinant CK1d ( Figure 1c ) and CK1e (Figure 1a, b and c) . Note that multiple bands are evident in the p53 proteins phosphorylated by the CK1 isoforms (see especially Figure 1c where the exposure is lighter); we have shown previously that the p53NK catalyses multisite phosphorylation of serine residues 4, 6 and 9 in murine p53 and generates multiple closely migrating bands in SDS gels (Knippschild et al., 1996; . In addition, recombinant human CK1d and CK1e are capable of phosphorylating a peptide based on the Nterminal amino acids of human p53 (data not shown). Two fusion proteins lacking the ®rst ten amino acids of p53 (FP279 and FP295) were poor substrates for CK1e (Figure 1a) . Similarly, a fusion protein, FP380, in which these residues were replaced with alanine residues, was no longer a substrate for either CK1d (Figure 1c ) or CK1e (Figure 1b) , consistent with these sites being the target residues. A control protein (GST-R) in which the CK1e coding sequence was cloned in the anti-sense orientation with respect to GST, had no protein kinase activity (Figure 1b) . Taken together, these data indicate that both CK1d and CK1e can phosphorylate p53 in vitro at the same sites as the cellular p53NK.
p53NK shows properties characteristic of CK1d and CK1e
To further explore the possibility that p53NK was an isoform(s) of CK1, three additional biochemical measurements were carried out. Firstly, the copuri®cation of cellular p53NK with 35 S-labelled CK1d or CK1e was investigated. Extracts from rat F111 cells were mixed with 35 S-labelled in vitro-translated rat CK1d or human CK1e, then partially puri®ed using the procedure described in Materials and methods. The data shown in Figure 2 are taken from the ®rst step, ion exchange chromatography on Mono Q H/R 5/5 columns. These elution pro®les show that p53NK activity co-eluted with either radiolabelled CK1d or CK1e; (note that the dierence in the positions at which the kinase eluted in Figure 2a versus b most Phosphorylation of p53 by the delta and epsilon isoforms of CK1. The GST-p53, GST-CK1d and GST-CK1e fusion proteins used in this experiment, which are described in Materials and Methods, were expressed in bacteria and puri®ed by anity chromatography on glutathione-sepharose 4B beads. Protein kinase assays were carried out as described in Materials and methods, and the phosphorylated products were separated by SDS ± PAGE on 12.5% gels and detected by autoradiography. The positions at which casein and the GST-p53 fusion proteins migrated on the SDS gels are indicated. GST-R in panel B is a fusion protein in which the CK1e cDNA was cloned into the vector in the anti-sense orientation. The product of this fusion was puri®ed and used in this experiment as a control likely occurred because two dierent Mono Q columns were used). Identical elution pro®les were obtained if the cellular extracts and the radiolabelled proteins were not mixed but chromatographed separately (data not shown). In addition, the kinase activity and 35 Sradiolabel continued to co-elute during further puri®cation on phosphvitin-sepharose 4B and Mono S columns (data not shown). (The similarity in the elution characteristics of CK1d and CK1e was not surprising since these isoforms show striking similarity to each other at the amino acid level, especially within their kinase domains (Fish et al., 1995; Graves et al., 1993; DeMaggio AJ, Christenson E and Hoekstra MF, submitted) . In addition to co-puri®cation with the radiolabelled proteins, partially puri®ed fractions containing p53NK activity could be inhibited by micromolar concentrations of IC261, an inhibitor which is speci®c for CK1d and e (data not shown; DeMaggio AJ, Christenson E and Hoekstra MF, submitted) .
The kinetic properties of the cellular p53NK (partially puri®ed from SV52 cells by a three-step procedure (see Materials and methods)) and the bacterially-expressed CK1 isoforms were also measured (using Lineweaver-Burk plots) and the data are summarised in Table 1 . When the p53 substrate FP267 was used, no signi®cant dierences were found in the K m values for p53NK, CK1d, CK1e. Moreover, the K m value was also similar for CK1eFS, which has an intact CK1e kinase domain, but has a frame-shift in the Cterminal domain such that the C-terminal 63 amino acids are substituted with 59 dierent amino acids followed by a stop codon (Materials and methods). Similarly, when casein was used as substrate, the behaviour of each of the enzymes was identical.
p53NK is recognised by a CK1d-speci®c monoclonal antibody
Immunological evidence also supports the idea that p53 and CK1d interact physiologically. At each stage of the puri®cation of p53NK from cells, the fractions were examined by Western blotting using 128A, a monoclonal antibody speci®c for CK1d which does not recognise the a, b, g or e isoforms (DeMaggio AJ, Christenson E and Hoekstra MF, submitted) . An example is shown in Figure 3 . Elution of p53NK from a Mono S column (the third stage in the puri®cation procedure) showed that a single peak of kinase activity was detectable upon elution with a gradient of NaCl. The appearance of CK1d by western analysis was observed only in the same fractions as those containing the kinase activity. Similar observations were made when fractions from earlier stages of the puri®cation procedure were examined (i.e. following fractionation using the Mono Q or phosvitinsepharose-4B columns; data not shown). The copuri®cation of CK1d protein with p53NK protein kinase activity over several fractionation regimes strongly supports the identity of CK1d as a p53-Nterminus-targeted protein kinase.
p53 is phosphorylated by CK1d in vivo
To determine whether the interaction between p53 and CK1d occurs physiologically, two approaches were taken. In the ®rst, murine SV3T3 cells were treated with the CK1d/e-speci®c inhibitor, IC261 (DeMaggio AJ, Christenson E and Hoekstra MF, submitted); SV3T3 cells were chosen because they express high levels of p53 which is phosphorylated extensively at the N-terminus (Milne et al., 1994 (Milne et al., , 1995 . The cells were labelled with 32 P-orthophosphate for 2 h, then treated for 1 h with 3 mM IC261 in DMSO; (cells were treated S-labelled in vitro-translated CK1d or CK1e, and the proteins were chromatographed on a Mono Q (H/R 5/5) column as described in Materials and methods. p53 kinase activity was measured using the GST-p53 fusion protein FP267 as substrate and the phosphorylated proteins were resolved by SDS ± PAGE on 12.5% gels and detected by autoradiography (upper panels a and b). Aliquots of each fraction from the Mono Q column were also separated by SDS ± PAGE and the gels were prepared for¯uorography using Enhance (Amersham) then exposed to X-ray ®lm at 7808C (lower panels in a and b). The dierent positions at which the peaks eluted in panel A as compared with panel B was the result of using two dierent Mono Q columns Phosphorylation of p53 by CK1d and CK1e U Knippschild et al with DMSO alone as control). In vitro measurements of the inhibition of CK1d and CK1e by IC261 con®rmed that, in each case, the kinase activities were inhibited by greater than 80% at a concentration of 3 mM (data not shown). The cells were then lysed and the phosphorylated p53 was immunoprecipitated and analysed by two-dimensional tryptic phosphopeptide mapping. Figure 4 shows the phosphopeptide pattern obtained in the mock treatment ( Figure 4a ). The ®rst cleavage site for trypsin in murine p53 is after the lysine residue at position 24: phosphorylation of p53 at serines 4, 6 and 9 (by CK1) and 15 (by DNA-PK or related kinases) would therefore be expected to give rise to multiply phosphorylated species of this peptide. Each subsequent addition of a phosphate will increase the mobility of the peptide towards the anode and reduce its migration with the solvent front during chromatography. The peptides labelled 1 ± 4 in Figure 4 therefore represent 1 to 4 moles of phosphate per mole of peptide respectively. (Mutation of serines 4, 6 and 9 abolished the appearance of peptides 2 ± 4 (data not shown).) Note that these data show only the number of phosphates in the peptide but fail to show the positions at which any number of phosphates are located. Figure  4b shows the phosphopeptide pattern of the p53 from cells were treated for 1 h with 3 mM IC261. In this case peptides 3 and 4 were not detectable while the intensity peptide 2 was reduced by about 50%. No changes in any of the other phosphopeptides were apparent with the exception of the loss of an unidenti®ed peptide migrating close to the origin. These data are entirely consistent with the phosphorylation of p53 by CK1d and/or CK1e in vivo. Figure 3 Partially puri®ed p53NK can be detected by a monoclonal antibody speci®c for CK1d. p53NK was partially puri®ed through three dierent columns as described in Materials and methods. p53NK activity (measured using the GST-p53 fusion protein FP267 as substrate) elutes from the third column (Mono S) as a single peak; the kinase activity of fractions 13 ± 18 are shown with p53NK eluting at fraction 16, corresponding to elution at approximately 320 mM NaCl. The Western blot showing the elution position of CK1d is shown in the lower panel Figure 4 Phosphorylation of p53 at N-terminal sites in vivo is inhibited by the CK1d-speci®c inhibitor IC261. SV3T3 cells were labelled using 32 P-orthophosphate as described in Materials and methods. One hour before harvesting, IC261 was added to the medium to a ®nal concentration of 3 mM. An equal volume of DMSO, the solvent for IC261, was added to control plates. The cells were lysed and the radiolabelled p53 proteins isolated by immunoprecipitation and SDS ± PAGE. Tryptic phosphopeptides were prepared and spotted onto thin layer plates at an origin (marked on each panel with an arrowhead). (a) shows p53 from untreated cells while (b) shows p53 from the IC261-treated cells. The lettering and numbering on the ®gure refer to individual phosphopeptides as follows: c, j and m are phosphopeptides arising from phosphorylation by CK2, JNK and MAP kinase respectively. p represents the position at which free phosphate migrates. Phosphopeptides 1 to 4 represent the N-terminus of p53 (amino acids 1 ± 24) containing 1 to 4 phosphate groups respectively (see text for an explanation) Using a dierent approach, COS-1 cells were transiently transfected with plasmids expressing wild type murine p53 together with a plasmid expressing a GFP-CK1d fusion protein (or GFP alone as control). To check that the CK1d portion was active as a protein kinase, the cells were lysed and the GFP fusion proteins immunoprecipitated using a GFP-speci®c monoclonal antibody. The immobilised proteins were then used to phosphorylate the p53 substrate FP267. The data ( Figure 5) show that the immunoprecipitated GFP-CK1d protein did indeed possess p53 kinase activity whereas the GFP alone was not able to phosphorylate p53. When the transiently-transfected cells were labelled with 32 P-orthophosphate, two additional phosphopeptides were observed in the mouse p53 immunoprecipitated from the cells overexpressing GFP-CK1d (Figure 6b , indicated with arrows), as compared with mouse p53 from the cells transfected with the GFP control plasmid (Figure 6a ). These peptides migrate very closely to the position of N-terminal peptide 2; neither these peptides nor peptide 2, 3, and 4 were observed when the COS-1 cells had been transfected with GFP-CK1d and p53 containing mutations at the phosphorylation sites, residues 4, 6 and 9 (data not shown). They are therefore likely to arise from phosphorylation at Nterminal residues including serines 4, 6 or 9. It is not clear why additional phosphopeptides are observed but a strong possibility is that high level expression of CK1d disrupts sequential addition of phosphates to these residues, or may lead to the increased phosphor-CK1δ CON
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Figure 5 Protein kinase activity of a GFP-CK1d fusion protein expressed in COS-1 cells and immunoprecipitated using an anti-GFP monoclonal antibody. COS-1 cells transfected with CK1d, a plasmid expressing a GFP-CK1d fusion protein (b), or pGFPcon which expresses only the GFP portion owing to a frame shift in the linker region (a). 60 ± 72 h after transfection, the cells were harvested and the GFP proteins were immunoprecipitated and washed in kinase buer as described in Materials and methods. The ability of the immunoprecipitated proteins to phosphorylate the p53 substrate FP267 was measured Figure 6 Hyper-phosphorylation of p53 at N-terminal sites in COS-1 cells following over-expression of a GFP-CK1d fusion protein. COS-1 cells were transfected with pCMVNc9 which expresses wild type mouse p53 together with pGFP-CK1d, a plasmid expressing a GFP-CK1d fusion protein (panel B), or pGFPcon which expresses only the GFP portion owing to a frame shift in the linker region (panel A), were labelled using 32 P-orthophosphate as described in Materials and methods. Cell lysis, immunoprecipitation and tryptic phosphopeptide analysis was carried out. The lettering and numbering on the ®gure are as described in the legend to Figure 4 . The two arrows in (B) highlight additional N-terminal phosphopeptides arising from overexpression of the kinase ylation of sites which may normally be phosphorylated to only a very low level; (eg serines 6 then 9 appear to be the preferred sites in vitro, followed by serine 4 ). This would generate species of the phosphopeptide which diered only in the positions of the phosphates and which could therefore have marginally dierent migration properties. Alternatively, constant on-phosphorylations could result in the formation of diester bonds between closely spaced phosphates or between phosphate residues and carboxyl side chains of neighbouring asp/glu residues.
CK1d, but not CK1e, is induced by etoposide and camptothecin Previous analysis of p53NK in MethAp53(ts) cells indicated that the activity of the kinase could be enhanced both by p53 and, in a p53-dependent manner, by the drugs camptothecin and etoposide (Knippschild et al., 1996) ; (this cell line expresses the valine 135 temperature-sensitive p53 which adopts a mutant conformation at 388C but a wild type conformation at 28 ± 328C (Otto and Deppert, 1993) ). To determine whether CK1d or e could be induced in a similar manner, the levels of mRNA for each of these kinases was measured by Northern analysis after p53 induction or treatment with the drugs in the MethAp53(ts) cells, at both the permissive and nonpermissive temperatures. The data (Figure 7a) indicated that, as had been shown previously (Graves et al., 1993) , there were two species of CK1d mRNA, at 1.9 kb and 2.2 kb respectively. There were no signi®cant dierences in the levels of CK1d mRNA when comparing the untreated cells grown as monolayers at the two dierent temperatures. However, when the cells grown at 288C were treated with either etoposide or camptothecin increases in the level of CK1d mRNA of up to 2.5-fold were observed. In contrast, at the non-permissive temperature, the levels of CK1d mRNA actually decreased slightly. These observations closely match the previously reported eects of wild type p53 conformation and DNA damage-inducing drugs on p53NK kinase activity (Knippschild et al., 1996) . When the levels of CK1e mRNA were examined under identical conditions, no increases were observed ( Figure 7B ). The only notable dierence was that CK1e mRNA decreased following camptothecin treatment at 388C.
When the levels of CK1d protein were measured in this cell line at the dierent temperatures and in the presence or absence of the drugs, similar results were obtained. Following ion exchange chromatography on a Mono Q column, the kinase activity (from cells grown at 288C) appeared predominantly in fraction 12, with some additional activity in fraction 13 (Figure 8a ; Mono Q fractionation prior to immunodetection allowed us to con®rm that the increased levels of CK1d protein co-fractionated with the p53NK protein kinase activity (data not shown)). Treatment with etoposide or camptothecin showed increases in the levels of CK1d in the peak fractions (fractions 11 ± 13) in line with the increases observed in CK1d mRNA. No such changes were observed when the cells were maintained at 388C (Figure 8b ; only fractions 12 from each treatment are shown). Taken together, the data from the Northern and Western analyses indicate that treatment of MethAp53(ts) cells with topoisomerasedirected (DNA damage-inducing) drugs can enhance the level of CK1d through a p53-dependent mechanism.
Discussion
Previously, we detected and characterised a p53-and DNA-damage-inducible p53 N-terminus-targeted protein kinase activity (p53NK) present in various cell lines including MethAp53(ts) cells (Knippschild et al., 1996) . In this paper, we show that two isoforms of the casein kinase 1 family, CK1d and CK1e (Fish et al., 1995; Graves et al., 1993) , which are highly related to each other, display properties characteristic of p53NK and can indeed phosphorylate p53 in the cell. At the biochemical level, CK1d and CK1e co-puri®y with p53NK ( Figure 2) Figure 7 Northern analysis of CK1d and CK1e mRNAs from drug-treated MethAp53(ts) cells. MethAp53(ts) cells were grown as monolayers at 388C, then shifted to 288C for 24 h and treated with 150 mM etoposide (Et) or 10 mM camptothecin (Cpt) for 2 h. Control cells received no additions (Co). The cells were harvested and the RNA was extracted and analysed by Northern blotting using 32 P-labelled full length cDNA probes for CK1d (rat, a) or CK1e (human, b). After detection by autoradiography, the ®lters were stripped and re-probed with a full length cDNA for wild type GAPDH Phosphorylation of p53 by CK1d and CK1e U Knippschild et al p53 in vitro ( Figure 1) ; they are also indistinguishable from each other with respect to their kinetic behaviour using either p53 or casein as substrates (Table 1) and can be inhibited by micromolar concentrations of the CK1d/e-speci®c inhibitor, IC261 (DeMaggio AJ, Christenson E and Hoekstra MF, submitted; data not shown). In addition to this, the availability of the monoclonal antibody 128A, which is speci®c for CK1d (DeMaggio AJ, Christenson E and Hoekstra MF, submitted) con®rmed that the p53NK co-puri®es with CK1d through three dierent steps (Figure 3 ). However, we cannot determine whether this also holds for CK1e as we do not have an isoform-speci®c antibody for CK1e which does not cross-react with CK1d. The data in this paper (Fig. 4) also support the idea that phosphorylation of p53 by CK1d and/or CK1e occurs in vivo since treatment of SV3T3 cells with the inhibitor IC261 leads to loss of phosphorylation at three sites within the N-terminus of p53. (Since the inhibitor IC261 can block the activity of both the CK1d and CK1e (but not a, b or g) isoforms in vitro (data not shown), we cannot attribute the loss in phosphorylation of p53 to either one of these two isoforms individually.) We have also shown that transient over-expression of CK1d leads to hyperphosphorylation of the N-terminus of p53 ( Figure 6 ). (Experiments involving transient over-expression were carried out because we have been unable to observe any signi®cant ectopic expression of CK1d in isolated clones, in spite of screening over 120 clones from four dierent cell types (data not shown). It is therefore possible that there is a strong selection against overexpression of this kinase in cells.) Strikingly, CK1d and CK1e (which map to dierent chromosomes (Fish et al., 1995) ) show a remarkable degree of similarity, especially within the protein kinase domain (98%) (Christenson et al., 1996; Fish et al., 1995; Graves et al., 1993) and it may be that they are either redundant in vivo, or that they are responsive to dierent signals or interact with dierent regulatory proteins, thereby placing a common set of substrates under control of (at least) two dierent regimes. The selective enhancement of CK1d by p53 in the MethAp53(ts) system (Figures 7 and 8) would tend to support the latter hypothesis. An additional factor to consider is that the levels of expression of the d and e isoforms of CK1 may be dependent upon cell or tissue type. Certainly in the MethAp53(ts) cells the level of CK1e mRNA was barely detectable as compared with CK1d mRNA and was not inducible (Figure 7 ). Moreover, we have observed dierent relative levels of CK1d and CK1e expression in a number of dierent cell lines (data not shown). Phosphorylation of p53 by both enzymes could therefore represent convergent regulation arising from dierent environmental conditions. The data are also consistent with a model in which the levels of p53 and CK1d may be interdependent, perhaps involving a regulatory loop. p53 is clearly phosphorylated by CK1d in vitro and in vivo (Figures 1,  4 and 6) while the induction of wild type p53 in MethAp53(ts) cells leads to enhanced levels of CK1d mRNA and protein (Figures 7 and 8) , and p53NK protein kinase activity (Knippschild et al., 1996) . Similar increases in the levels of CK1d protein were observed in primary murine ®broblasts upon drug treatment (data not shown) indicating that the eect is not restricted to the MethAp53(ts) cells. Moreover, the demonstration that CK1d is a p53-responsive protein kinase adds weight to the evidence that identi®es CK1d as p53NK. The mechanism of the induction of the protein kinase is not clear and may occur either through p53-dependent transactivation of the CK1d promoter or through a post-transcriptional eect. Alternatively, increased levels of CK1d may re¯ect a p53-dependent enrichment of cells at speci®c stages of the cell cycle at which the kinase is present in an activated form.
The key issue which should now be addressed is the biological consequence of the interplay between p53 and CK1d. CK1 isoforms are thought to be involved in the regulation of DNA repair and chromosomal segregation. For example, the S. cerevisiae hrr 25 gene encodes a protein kinase with striking similarity to CK1 family members: hrr 25 mutants show sensitivity to DNA damage and have defects in nuclear segregation and meiotic division (Hoekstra et al., 1991) . Two genes in S. pombe, hhp 1 and hhp 2, may play similar roles to hrr 25 and deletion of these genes generates large cells containing multiple nuclei (i.e. polypolidy; Dhillon and Hoekstra, 1994) . DMCK1, (the homologue of CK1a in D. melanogaster) is activated following DNA damage and relocates to the nucleus (Santos et al., 1996) , while mammalian CK1a is both thought to be involved in controlling DNA replication (Cegielska and Virshup, 1993) and in events at the mitotic spindle (Brockman et al., 1992) . Control cells received no additions (Con). The cells were lysed, and the proteins were fractionated by ion exchange chromatography using a Mono Q (H/R 5/5) column and eluting with a linear gradient of NaCl. The peak fractions were analysed by SDS-PAGE on 10% gels and subsequently transferred to membranes. Fractions containing the peak of p53NK activity (fractions 11, 12 and 13) from the cells grown at 288C are shown in (a). The fraction containing the peak of p53NK activity (fraction 12) from the cells grown at 388C is shown in (b). The presence of CK1d was detected using the CK1d-speci®c monoclonal antibody 128A
Phosphorylation of p53 by CK1d and CK1e U Knippschild et al CK1d and CK1e, (the mammalian CK1 isoforms which show the greatest degree of similarity to HRR25), but not CK1a, can complement hrr 25 mutations in yeast, suggesting that the mammalian and yeast proteins may have functional similarity (Graves et al., 1993; DeMaggio AJ, Christenson E and Hoekstra MF, submitted) . p53 is also a protein with established roles in the G1 (Kastan et al., 1991 Kuerbitz et al., 1992) and G2 (Aloni et al., 1995; Cross et al., 1995; Paules et al., 1995) checkpoints which monitor chromosomal aberrations and segregation respectively. The activation of p53 at these checkpoints is strikingly co-incident with the proposed role of CK1 and the interaction of these two proteins may therefore play a pivotal role in mechanism(s) of sensitivity to DNA damage at these checkpoints.
Materials and Methods
Cell lines
The following cell lines were used in this study: COS-1, SV3T3, F111, FR(wt648) (a rat F111 ®broblast line transformed by SV40 (Pintel et al., 1981) ), SV-52 (a REF52 cell line transformed by SV40 (Graessmann and Graessmann, 1983) ) and MethAp53(ts). The parental MethA' cell line was originally isolated as a methylcholanthrene transformant. MethAp53(ts) cells were established after transfection of BALB/c mouse MethA tumour cells with the`valine 135' temperature-sensitive murine p53 in the plasmid vector pLTRcGval135 (Otto and Deppert, 1993) . Cells were grown in Dulbecco-Vogt modi®ed Eagle's medium (DMEM) supplemented with either 5% FBS plus 200 mg/ml G418 (MethAp53(ts), or 10% FBS (COS-1 cells, FR(wt648), SV-52 and SV3T3 cells) and incubated at 378C (COS-1 cells, FR(wt648), SV-52 and SV3T3 cells) or 398C (MethAp53(ts)) in a humidi®ed 5% carbon dioxide atmosphere. In some experiments, MethAp53(ts) cells were also shifted to 288C for 24 h.
Oligonucleotides, PCR and plasmids
The two oligonucleotide primers used for polymerase chain reaction (PCR) ampli®cation of human CK1e were (5' to 3') ATGGAGCTACGTGTGGGGAAC (5') and TCACTTCCCGAGATGGTAAATG (3'); for rat CK1d the primers were ATGGAGCTAGGGTCGGGAATAG (5') and TCAGTAGGTGGTACGTCGTGG (3'). A full length human CK1e cDNA was isolated by PCR using a human liver cDNA library (kindly provided from P Hall, Dundee). RT ± PCR was used to obtain a full length rat CK1d cDNA using RNA extracted from FR(wt648) cells. The PCR conditions were annealing at 508C (CK1e) or 61.58C (CK1d) for 1 min, elongation at 728C for 2 min and denaturation at 958C for 30 s. The resulting fragments were cloned into pCRII (Invitrogen) and fully sequenced using the USB Sequencing Kit (Amersham) and appropriate sequencing oligonucleotides. DNA sequence analysis revealed that the predicted amino acid sequence of the CK1d cDNA showed one change in comparison with the published sequence (Graves et al., 1993) , that of Lys 223 (AAG) to Arg (AGG). The predicted amino acid sequence for CK1e showed a number of changes from the published sequence (Fish et al., 1995) ; these were: Ser 101 to Ile, Gln 271 to His, Leu 272 to Val (all within the kinase domain); and Gly 332 to Ala; Pro 333 to Ala; Pro 348 to Gln; Val 370 to Ala and Pro 403 to Ser (all within the C-terminal non-catalytic domain). A further change from the published sequence, a point insertion of a C at codon 352, was also evident and when expressed yielded a truncated CK1e product. (This clone, termed CK1eFS (frame shift), substitutes 59 dierent amino acids followed by a stop codon and therefore eectively deletes the Cterminal 63 amino acids. This clone was examined together with the other CK1 isoforms in kinetic experiments.) All of the CK1e clones isolated by PCR showed these changes (data not shown). To obtain, a CK1e product with the same C-terminus as the published sequence, the additional C at codon was deleted by oligonucleotide-directed mutagenesis using the oligonucleotide (5' to 3') CGA-GAGGCAGGGGTAGAAGC. The template for mutagenesis was the pCRII-CK1e product which had been rescued in single-stranded form following infection of the bacterial cells with the helper phage KO7.
Plasmid pCMVNc9 expresses a wild type murine p53 cDNA under control of the CMV early promoter (Eliyahu et al., 1988 (Eliyahu et al., , 1989 . pCMV-triple is a derivative of this plasmid in which the codons for serine residues 4, 6 and 9 (this sites phosphorylated by CK1) have been mutated by oligonucleotide-directed mutagenesis to encode alanine residues. The mutagenesis was carried out as described previously using the oligonucleotide (5' to 3') GGAGGAGG-CACAGGCGGATATCGCCCTCGAG and a singlestranded p53 cDNA template in the M13 vector tg130 (Amersham). Complete sequence analysis of this cDNA revealed no other changes in the coding region (data not shown).
Plasmid pGFP-CK1d, which expressed a green¯uorescent protein (GFP)-CK1d fusion protein using the CMV promoter, was constructed by cloning the full length PCRgenerated CK1d cDNA into a modi®ed version of the vector phGFPS65T (Clontech Labs Inc). A control plasmid pGFPcon, is identical except that it has a point deletion in the linker between the GFP and CK1d coding sequences which introduces an in frame stop codon immediately upstream of the CK1d coding sequence.
Expression and puri®cation of glutathione S-transferase fusion proteins
The recombinant glutathione S-transferase fusion proteins were expressed in Escherichia coli using the vector pGEX-2T (Amrad Corp.). The construction, expression and puri®cation of recombinant glutathione S-transferase-p53 (GST-p53) fusion proteins has been described in detail elsewhere (Milne et al., 1994 (Milne et al., , 1995 . In short, FP267 contains a fragment encoding the ®rst 1 ± 64 amino acids of wild type mouse p53 with potential phosphorylation sites for CK1, DNA-PK and JNK1. FP222 contains codons 1 ± 85 of wild type mouse p53 in the antisense orientation, FP279 expresses mouse p53 codons 11 ± 63, and FP295 also expresses codons 11 ± 63 but has a serine to alanine mutation at position 34. FP380 (which has not been reported previously) comprises amino acids 1 ± 85 of murine p53 but with serine to alanine changes at residues 4, 6 and 9. The GST-protein kinase fusion protein expression plasmids were as follows: to construct pGSTCK1e, an EcoRI fragment encoding the full length human CK1e was cloned into pGEX-2T in the correct orientation; (a plasmid in which this fragment was cloned in the opposite orientation (pGST-R) was used as a control in some experiments; the CK1eFS cDNA was also cloned into pGEX-2T to give pGST-CK1eFS). Similarly, an EcoRI fragment encoding rat CK1d (again isolated by PCR) was cloned in the sense orientation into pGEX-2T to give plasmid pGST-CK1d.
Fusion proteins were isolated by incubation of the GSTp53 bacterial lysates with glutathione-Sepharose 4B beads (Pharmacia Biotech Inc.) at 48C for 1 h. The beads were washed three times with 50 mM Tris (pH 7.5). Fusion proteins were eluted from the beads by incubating with Phosphorylation of p53 by CK1d and CK1e U Knippschild et al 50 mM Tris buer (pH 7.5) and 5 mM reduced glutathione. Eluted fusion proteins were used immediately as signi®cant loss of activity occurred upon various regimes of storage.
Puri®cation of p53 N-terminus-targeted protein kinase
Mammalian cells (F111, SV-52 or MethAp53(ts)) were washed three times in ice-cold PBS then lysed in 20 mM Tris-acetate (pH 7.0) 0.27 M sucrose, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 10 mM sodium b-glycerophosphate, 50 mM NaF, 1 mM benzamidine, 4 mg/ml leupeptin and 0.1 % b-mercaptoethanol. Alternatively, nuclear extracts were prepared as follows. Cells were washed twice with KM buer (10 mM MOPS (pH 6.8), 10 mM NaCl, 1.5 mM MgCl 2 , 1 mM EDTA, 5 mM dithiothreitol, 10% (v/v) glycerol) and then lysed in 2 ml per plate of KM buer containing 1% (v/v) Nonidet P-40 (NP-40) for 30 min at 48C The remaining structures were washed with KM buer then lysed as described above. Whole cell extracts or nuclear extracts were passed through 0.22 mm ®lters and 4 ± 6 mg applied to a MonoQ (H/R 5/5) column or 360 ± 600 mg to a HiTrap Q column attached to the FPLC system (Pharmacia Biotech). The proteins were then eluted with a linear gradient of sodium chloride in buer A: (comprising 50 mM Tris (pH 7.5), 1 mM EDTA, 1 mM EGTA, 5% glycerol, 0.03% Brij35, 1 mM benzamidine, 4 mg/ml leupeptin, 0.1% b-mercaptoethanol). Fractions were screened for p53 kinase activity as described previously . Peak fractions were diluted in buer A and applied to a phosvitin-sepharose 4B column, then eluted stepwise using increasing concentrations of NaCl to 600 mM with 50 mM increments . Fractions containing p53NK activity were diluted in buer A and applied to a MonoS H/R 5/5 column (Pharmacia Biotech). As before the proteins were eluted with a linear gradient of increasing NaCl concentration. Attempts to further purify the kinase after this step consistently led to complete loss of kinase activity.
Blotted protein kinase assaỳ
Blotted protein kinase' assays were carried out using the procedure of Ferrell and Martin (1991) . Peak fractions of kinase activity from MethAp53(ts) cell extracts chromatographed on a MonoQ (H/R 5/5) column (Pharmacia Biotech) were separated by SDS ± PAGE on a 12.5% polyacrylamide gel containing 150 mg FP267, then transferred to a nylon membrane (Immobilon, Millipore) at 48C in 25 mM Tris, 192 mM glycine (pH 8.3), without methanol as transfer buer. The ®lter was washed several times in ice cold denaturation buer (7 M guanidine hydrochloride, 50 mM Tris (pH 8.3), 50 mM dithiothreitol, 2 mM EDTA, 1% (w/v) BSA) and incubated in denaturation buer for 16 h at 48C. The ®lter was rinsed in 50 mM Tris (pH 7.4) and incubated in renaturation buer (140 mM NaCl, 10 mM Tris (pH 7.4), 2 mM DTT, 1% (w/v) BSA, 0.1% (v/v) NP-40) at 48C for 24 h. The ®lter was blocked by incubation in 30 mM Tris (pH 7.4), 1% (w/v) FP267 for 1 h at room temperature, then washed and ®nally incubated in reaction buer (10 mM MgCl 2 , 25 mM Tris (pH 7.4), 0.1 mM EDTA and 20 mM ATP containing 100 mCi/ml [g-32 P]ATP) for 1 h at 308C. The ®lter was washed twice with 30 mM Tris (pH 7.4), once with 30 mM Tris (pH 7.4), 0.05% NP-40, twice 30 mM Tris (pH 7.4), once with 1 M KOH, and twice with 30 mM Tris (pH 7.4) for 10 min each at room temperature. The ®lter was subsequently dried and exposed to Fuji RX ®lm at 7808C with intensifying screens.
Standard protein kinase assays
p53 kinase assays were carried out using puri®ed GST-p53 fusion proteins FP267, FP279, FP295 or FP380 as substrates. The substrate protein was resuspended in a total volume of 20 ml containing 25 mM Tris (pH 7.5) 10 mM MgCl 2 , 0.1 mM EDTA, 1 mM sodium orthovanadate and 20 mM [g-32 P]ATP (speci®c activity 5 Ci/mmol). The reactions were initiated by the addition of enzyme (usually 2 ml of 1 ml fractions eluted from Mono Q, HiTrap, or phosvitin-sepharose 4B columns, or 10 ml of recombinant GST-CK1d, GST-CK1e or GST-R) and incubated for 30 min at 308C. Kinase assays were also performed in the presence of 3 mM IC261, a CK1d speci®c inhibitor (DeMaggio AJ, Christenson E and Hoekstra MF, submitted). Alternatively transiently expressed GFP-CK1d fusion protein was immunoprecipitated from COS-1 cell extracts using a GFP-speci®c monoclonal antibody (Clontech) and the immobilised fusion protein used as the source of kinase. The reactions were stopped by adding 5 ml of concentrated SDS sample buer (75% (v/v) bmercaptoethanol, 20% (w/v) SDS, 10% (v/v) glycerol and 0.02% (w/v) bromphenol blue). Reaction products were separated by SDS-PAGE on 12.5% gels and the phosphorylated proteins visualised by autoradiography. For quantitative analysis, the phosphorylated products were excised from the gel and Cerenkov radiation was measured using a scintillation counter.
Phosphopeptide analysis
SV3T3 cells were labelled with 5 mCi 32 P-orthophosphate per 10 cm plate for 3 h as described previously (Milne et al., 1994) . One hour prior to harvesting, the CK1d-speci®c inhibitor IC261 (DeMaggio AJ, Christenson E and Hoekstra MF, submitted) was added to a ®nal concentration of 3 mM; an equal volume of DMSO, the solvent for the inhibitor, was added to control plates. For the COS-1 cell labelling experiments, the cells were transiently cotransfected with plasmids expressing wt (pCMVNc9) or phosphorylation-site mutant (pCMV-triple) mouse p53 and either the full-length GFP-CK1d fusion protein or the truncated fusion protein as control (pGFP-CK1d and pGFP-con respectively). COS-1 cells were labelled with 32 P-orthophosphate for 30 min. In each case p53 was immunoprecipitated with PAb421 or PAb246 and separated by SDS ± PAGE on 12.5% polyacrylamide gels. The gels were then blotted onto a membrane (Immobilon-P, Millipore) and the radioactive bands containing phosphorylated p53 were detected by autoradiography and excised for further analysis (Luo et al., 1991) . Excised membrane fragments were incubated in 100 mM acetic acid, 5% polyvinylpyrrolidone (PVP-360, Sigma) at 378C, extensively washed with water and 50 mM ammonium bicarbonate buer, digested with trypsin and oxidised with performic acid for 1 h. Phosphopeptides were separated in two dimensions on cellulose thin-layer plates by electrophoresis at pH 1.9, followed by ascending chromatography (Meek and Eckhart, 1988) and subsequently visualised by autoradiography.
Transient transfections
Cells were seeded at a density of 10 6 per 10 cm plate. A total of 4 mg of plasmid DNA were transfected per 10 cm plates by mixing the DNA with Lipofectamine reagent (Gibco) in FBS-free MEM, according to the manufacturer's instructions. All subsequent procedures were carried out as described by the manufacturer. Analysis of transientlytransfected cells was performed 60 ± 72 h after transfection.
In vitro transcription and translation
In vitro transcription (from the SP6 promoter) and translation (in the presence of [
35 S]methionine) of pCRIIderivative plasmids encoding CK1d and CKe cDNAs was Phosphorylation of p53 by CK1d and CK1e U Knippschild et al carried out using the TNT SP6 coupled reticulocyte lysate system (Promega) according to the manufacturer's instructions.
Comparative kintetic analysis of CK1 isoforms
Kinetic analyses were carried out using recombinant GSTCK1d, GST-CK1e, GST-CK1eFS and p53NK which was partially puri®ed from SV-52 cells using the regime described above. Kinase reactions were performed for each enzyme preparation at 308C for 15 min in a total volume of 25 ml using dierent amounts of substrates: 8.2 mg, 4.1 mg, 2 mg, 1 mg, 0.5 mg and 0.25 mg of FP267; and 10 mg, 5 mg, 2.5 mg, 1.25 mg, 0.75 mg and 0.38 mg of casein (Sigma).
Northern blot analysis
Total cellular RNA was extracted as described by Sambrook et al. (1989) . For Northern Blot analysis total RNA (5 mlg) was denatured with 6.3% formaldehyde and 50% formamide and separated on 1% agarose/formaldehyde gels. Transfer of RNA to Magnacharge nylon membranes (Micron Separations Inc) by capillary blotting and hybridisation were performed by standard methods (Sambrook et al., 1989) . The blots were hybridised with 32 P-labelled CK1d or CK1e cDNA probes or, alternatively with a 32 P-labelled GAPDH cDNA as control. Hybridisation was performed under stringent conditions (50% formamide, 56SSPE, 0.5% SDS, 56Denhardt's solution, 5% dextran sulphate and 100 mg/ml denatured salmon sperm DNA) at 488C, and the blots were washed several times at 558C in 26SSC containing 0.1% SDS.
Western blotting
Steady state levels of CK1d were determined by Western analysis. Gels were transferred to Immobilon-P membrane (Millipore) and probed with the CK1d-speci®c monoclonal antibody 128A (DeMaggio AJ, Christenson E and Hoekstra MF, submitted). Detection was carried out using horse radish peroxidase-conjugated anti-mouse IgG as a secondary antibody, followed by chemiluminescence detection (ECL, Amersham).
